Physician profile
Philip C Smith
NPI 1942206149
$4,991.80
in general payments reported to CMS, 2019-2025
21 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $221 · 2021: $517 · 2022: $609 · 2023: $374 · 2024: $2,152 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Travel and Lodging: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.08 |
| Travel and Lodging | $1,439.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,903.56 | 2019-2025 | Lensx, Clareon, Precision 7 |
| Novartis Pharmaceuticals Corporation | $321.25 | 2020-2023 | |
| Mallinckrodt Hospital Products INC. | $296.73 | 2020-2025 | Acthar |
| Abbvie INC. | $266.24 | 2022-2025 | Durysta |
| Bausch & Lomb Americas INC. | $166.71 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Amgen INC. | $133.27 | 2024-2025 | Tepezza |
| Glaukos Corporation | $129.60 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $128.67 | 2019-2024 | Acuvue |
| Allergan, INC. | $108.54 | 2019-2022 | |
| Rxsight INC | $101.13 | 2022 | |
| Oyster Point Pharma, INC. | $80.69 | 2023-2024 | Tyrvaya |
| Biotissue Holdings INC. | $71.55 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $61.37 | 2022-2023 | Purified Cortrophin Gel |
| Shire North American Group INC | $53.05 | 2019 | |
| Aerie Pharmaceuticals, INC. | $50.72 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $26.40 | 2021-2022 | |
| Horizon Therapeutics Plc | $24.39 | 2022 | |
| Thea Pharma INC. | $20.19 | 2024 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $19.14 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.65 | 2019 | |
| Travere Therapeutics, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.